首页/数据集/Armata Pharmaceuticals liabilities 2020 to 2024

Armata Pharmaceuticals liabilities 2020 to 2024

Statista2026-04-11 收录

生物制药分析

企业负债评估

数据链接：

https://www.statista.com/statistics/1512147/armata-pharmaceuticals-liabilities/数据链接链接失效反馈

官方服务：

资源简介：

Liabilities of Armata Pharmaceuticals from 2020 to 2024 (in million U.S. dollars)

应用场景：

抗体表征

生物制药分析

Determining and linking the structural heterogeneity of recombinant antibodies to function is critical in the biopharmaceutical industry. We introduce a new microfluidic capillary electrophoresis—mass

DataCite Commons2024-02-15 更新90

19 F Dark-State Exchange Saturation Transfer NMR Reveals Reversible Formation of Protein-Specific Large Clusters in High-Concentration Protein Mixtures

蛋白质聚集表征

生物制药分析

Proteins frequently exist as high-concentration mixtures, both in biological environments and increasingly in biopharmaceutical co-formulations. Such crowded conditions promote protein–protein interac

NIAID Data Ecosystem30

Alr Technologies Inc. liabilities 2010-2021

公司财务分析

企业负债评估

Liabilities of Alr Technologies Inc. from 2010 to 2021 (in million U.S. dollars)

Statista30

Maquia Capital Acquisition Corp liabilities 2021-2023

SPAC财务分析

企业负债评估

Liabilities of Maquia Capital Acquisition Corp from 2021 to 2023 (in million U.S. dollars)

Statista50

Monopar Therapeutics liabilities 2020 to 2024